845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
| Autor: | Kirkwood, J.M., Zakharia, Y., Davar, D., Buchbinder, E., Medina, T., Daud, A., Ribas, A., Chmielowski, B., Niu, J.J., Gibney, G.T., Margolin, K.A., Olszanski, A.J., Mehmi, I., Sato, T., Shaheen, M., Zhao, L., Bobilev, D., Krieg, A.M., Wooldridge, J., Milhem, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S936-S936 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|